Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Rizzieri

Showing results (51-60 of 132) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemiaArati V Rao, Peter J M Valk, Klaus H Metzeler, et al.
Haematologica|January 15, 2026
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness levelNaveen Pemmaraju, Marco Herling, Kendra L Sweet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2022
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Kendra L Sweet, Anthony S Stein, et al.
Blood|February 10, 2009
Patterns of microRNA expression characterize stages of human B-cell differentiationJenny Zhang, Dereje D Jima, Cassandra Jacobs, et al.
Cancer|March 26, 2004
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251David A Rizzieri, Jeffrey L Johnson, Donna Niedzwiecki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 19, 2016
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple MyelomaDharshan Sivaraj, Michael M Green, Zhiguo Li, et al.
Blood|May 9, 2009
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)H Miles Prince, Dirk Hönemann, Andrew Spencer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemiaDavid A Rizzieri, Adam J Bass, Gary L Rosner, et al.
Journal of Personalized Medicine|November 27, 2021
CVD Risk Factors in the Ukrainian Roma and Meta-Analysis of Their Prevalence in Roma Populations WorldwideMatea Zajc Petranović, Ashley Elizabeth Rizzieri, Dharshan Sivaraj, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 28, 2010
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioningJunya Kanda, David A Rizzieri, Cristina Gasparetto, et al.
Pageof 14

Showing results (51-60 of 132) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemiaArati V Rao, Peter J M Valk, Klaus H Metzeler, et al.
Haematologica|January 15, 2026
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness levelNaveen Pemmaraju, Marco Herling, Kendra L Sweet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2022
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Kendra L Sweet, Anthony S Stein, et al.
Blood|February 10, 2009
Patterns of microRNA expression characterize stages of human B-cell differentiationJenny Zhang, Dereje D Jima, Cassandra Jacobs, et al.
Cancer|March 26, 2004
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251David A Rizzieri, Jeffrey L Johnson, Donna Niedzwiecki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 19, 2016
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple MyelomaDharshan Sivaraj, Michael M Green, Zhiguo Li, et al.
Blood|May 9, 2009
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)H Miles Prince, Dirk Hönemann, Andrew Spencer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemiaDavid A Rizzieri, Adam J Bass, Gary L Rosner, et al.
Journal of Personalized Medicine|November 27, 2021
CVD Risk Factors in the Ukrainian Roma and Meta-Analysis of Their Prevalence in Roma Populations WorldwideMatea Zajc Petranović, Ashley Elizabeth Rizzieri, Dharshan Sivaraj, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 28, 2010
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioningJunya Kanda, David A Rizzieri, Cristina Gasparetto, et al.
Pageof 14